drugset / Trial / NCT01505673

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

NCT01505673

Phase 4 Completed 71 enrolled Ildiko Lingvay Novo Nordisk A/S · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a high-dose insulin regimen (\>1.8 units/kg/day) in patients with uncontrolled (HbA1c \>7.5%) type 2 diabetes mellitus will improve blood sugar control. It also evaluates the effect of liraglutide on liver and pancreatic fat content, explores the mechanism of blood sugar improvement by assessing weight and pancreatic hormone release, and assesses blood pressure, lipid profile, and liver function. Finally it will look at patient quality of life and safety.

Timeline

Start
2012-01
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 1.8 mg Subcutaneous